留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

心脑血管疾病的治疗新策略：激活压力感受性反射

张丽丽,  刘爱军,  陈磊,  宋洪涛

downloadPDF
文章导航 > 药学实践与服务  > 2017 >  35(4): 294-297,345
张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略：激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
引用本文: 张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略：激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
shu
ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
Citation: ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
shu

心脑血管疾病的治疗新策略：激活压力感受性反射

doi: 10.3969/j.issn.1006-0111.2017.04.002
  • 1.

    福州总医院药学科, 福建 福州 350025

  • 2.

    第二军医大学药学院药理学教研室, 上海 200433

New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy

  • 1.

    Department of Pharmacy, Fuzhou General Hospital, Fuzhou 350025, China

  • 2.

    Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 我国心脑血管疾病的发病人数和死亡人数持续升高，动脉压力感受性反射（arterial baroreflex， ABR）功能受损与许多心脑血管疾病（如高血压、心衰等）的发生、发展密切相关。美国CVRx公司研发的Barostim neoTM仪器可以实现慢性刺激颈动脉窦处的压力感受器，激活压力反射，从而降低血压和心率，用于治疗顽固性高血压、心衰、终末期肾损伤等疾病。其治疗疾病的主要机制是抑制交感神经系统和肾素-血管紧张素系统，增强迷走神经的活动，进而改善压力感受性反射敏感性（baroreflex sensitivity， BRS）和心率变异性，恢复关键脏器的结构和功能。
    Abstract: The incident number and death toll of cardio-cerebrovascular diseases increase continuously in China. The impairment of arterial baroreflex (ABR) is closely related to the genesis and development of cardio-cerebrovascular diseases (such as hypertension and chronic heart failure). Barostim neoTM (by American CRVx. Inc) can reduce blood pressure and heart rate by electrically stimulating carotid sinus baroreceptors and activating baroreflex. Therefore, it can be used to treat resistant hypertension, heart failure and end-stage renal disease, etc. The mechanism of baroreflex activation therapy (BAT) includes inhibiting sympathetic nervous system and rennin-angiotensin system, and increasing the activity of vagus nerve. Thus it improves baroreflex sensitivity and heart rate variability, and restores the structure and function of key organs.
  • [1] GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053):1459-1544.
    [2] Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA, 2003, 289(19):2560-2572.
    [3] Dauphinot V, Kossovsky MP, Gueyffier F, et al. Impaired baroreflex sensitivity and the risks of new-onset ambulatory hypertension, in an elderly population-based study[J]. Int J Cardiol, 2013, 168(4):4010-4014.
    [4] Grassi G, Seravalle G, Brambilla G, et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension[J]. Int J Cardiol, 2014, 177(3):1020-1025.
    [5] Pinna GD, Maestri R, Capomolla S, et al. Applicability and clinical relevance of the transfer function method in the assessment of baroreflex sensitivity in heart failure patients[J]. J Am Coll Cardiol, 2005, 46(7):1314-1321.
    [6] 苏定冯.动脉压力感受性反射与心血管疾病[M].//苏定冯,缪朝玉,主编.心血管药理学.2版,北京:科学出版社,2010:101-109.
    [7] Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients[J]. Hypertension, 2010, 55(3):619-626.
    [8] Shen MJ, Zipes DP. Interventional and device-based autonomic modulation in heart failure[J]. Heart Fail Clin, 2015, 11(2):337-348.
    [9] Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment[J]. Cardiol Clin, 2010, 28(4):639-654.
    [10] Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial[J]. J Am Soc Hypertens, 2012, 6(4):270-276.
    [11] Mozaffarian D, Benjamin EJ, Go AS,et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association[J]. Circulation, 2016, 133(4):e38-360.
    [12] Forfar JC. Neuroendocrine activation in congestive heart failure[J]. Am J Cardiol, 1991, 67(12):3C-5C.
    [13] Keivanidou A, Fotiou D, Arnaoutoglou C, et al. Evaluation of autonomic imbalance in patients with heart failure: a preliminary study of pupillomotor function[J]. Cardiol J, 2010, 17(1):65-72.
    [14] Abraham WT, Zile MR, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction[J]. JACC Heart Fail, 2015, 3(6):487-496.
    [15] Richards AM, Troughton R, Lainchbury J, et al. Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies[J]. J Card Fail, 2005, 11(5 Suppl):S34-37.
    [16] Collins AJ, Foley RN, Gilbertson DT, et al. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis[J]. Clin J Am Soc Nephrol, 2009, 4 (Suppl 1):S5-11.
    [17] Converse RL, Jr., Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure[J]. N Engl J Med, 1992, 327(27):1912-1918.
    [18] Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease[J]. Circulation, 2002, 105(11):1354-1359.
    [19] Beige J, Koziolek MJ, Hennig G, et al. Baroreflex activation therapy in patients with end-stage renal failure: proof of concept[J]. J Hypertens, 2015, 33(11):2344-2349.
    [20] Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?[J]. Kidney Int, 2013, 83(3):377-383.
    [21] Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients[J]. BMJ, 1989, 298(6681):1152-1157.
    [22] Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension[J]. N Engl J Med, 1989, 321(13):868-873.
    [23] Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin[J]. Diabetes Obes Metab, 2006, 8(4):456-465.
    [24] Wallbach M, Lehnig LY, Helms HJ, et al. Long-term effects of baroreflex activation therapy on glucose metabolism[J]. Acta Diabetol, 2015, 52(5):829-835.
    [25] Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease[J]. Curr Hypertens Rep, 2001, 3 (Supp11):S3-S9.
    [26] Lohmeier TE, Iliescu R, Dwyer TM, et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex[J]. Am J Physiol Heart Circ Physiol, 2010, 299(2):H402-H409.
    [27] Lohmeier TE, Iliescu R. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation[J]. J Appl Physiol, 2012, 113(10):1652-1658.
    [28] Alnima T, de Leeuw PW, Tan FE, et al, Rheos Pivotal Trial I. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension[J]. Hypertension, 2013, 61(6):1334-1339.
    [29] Lohmeier TE, Iliescu R, Liu B, et al. Systemic and renal-specific sympathoinhibition in obesity hypertension[J]. Hypertension, 2012, 59(2):331-338.
    [30] Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial[J]. J Am Soc Hypertens, 2012, 6(2):152-158.
    [31] Bisognano JD, Kaufman CL, Bach DS, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system[J]. J Am Coll Cardiol, 2011, 57(17):1787-1788.
    [32] La Rovere MT, Christensen JH. The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs[J]. Vascul Pharmacol, 2015, 71:1-10.
    [33] Gronda E, Seravalle G, Trevano FQ, et al. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction[J]. J Hypertens, 2015, 33(8):1704-1708.
    [34] Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present, and future[J]. Curr Hypertens Rep, 2010, 12(2):61-66.
  • [1] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [2] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [3] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [4] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [5] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [6] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [7] 李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华.  米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
    [8] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
    [9] 陈金涛, 乔子婴, 马明华, 张若曦, 王振伟, 年华.  基于网络药理学和分子对接技术研究金芪清疏颗粒治疗社区获得性肺炎的潜在机制 . 药学实践与服务, 2024, 42(11): 471-478. doi: 10.12206/j.issn.2097-2024.202312014
    [10] 张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲.  新斯的明与山莨菪碱联合应用对肺型氧中毒的保护作用及其机制的研究 . 药学实践与服务, 2024, 42(10): 433-438, 444. doi: 10.12206/j.issn.2097-2024.202310049
    [11] 岳春华, 贲永光, 王海桥.  基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
    [12] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [13] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [14] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [15] 钱淑雨, 李铁军.  耐碳青霉烯类肠杆菌耐药机制的研究进展 . 药学实践与服务, 2024, 42(10): 419-425. doi: 10.12206/j.issn.2097-2024.202405005
    [16] 杨彬, 王作君, 陈菡, 张敬一.  基于DRGs的医院合理用药管理机制探索实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404030
    [17] 李清, 郭宜银, 陈颖, 瞿发林, 董文燊, 戈煜.  夜宁胶囊对小鼠镇静催眠作用及其机制的研究 . 药学实践与服务, 2024, 42(8): 346-349. doi: 10.12206/j.issn.2097-2024.202211047
    [18] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [19] 徐璐璐, 刘爱军.  丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
    [20] 陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼.  通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3955
  • HTML全文浏览量:  1144
  • PDF下载量:  1643
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-12-26
  • 修回日期:  2017-03-20

心脑血管疾病的治疗新策略：激活压力感受性反射

doi: 10.3969/j.issn.1006-0111.2017.04.002
  • 1. 福州总医院药学科, 福建 福州 350025
  • 2. 第二军医大学药学院药理学教研室, 上海 200433
  • 收稿日期: 2016-12-26
  • 修回日期: 2017-03-20

摘要: 我国心脑血管疾病的发病人数和死亡人数持续升高，动脉压力感受性反射（arterial baroreflex， ABR）功能受损与许多心脑血管疾病（如高血压、心衰等）的发生、发展密切相关。美国CVRx公司研发的Barostim neoTM仪器可以实现慢性刺激颈动脉窦处的压力感受器，激活压力反射，从而降低血压和心率，用于治疗顽固性高血压、心衰、终末期肾损伤等疾病。其治疗疾病的主要机制是抑制交感神经系统和肾素-血管紧张素系统，增强迷走神经的活动，进而改善压力感受性反射敏感性（baroreflex sensitivity， BRS）和心率变异性，恢复关键脏器的结构和功能。

English Abstract

张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略：激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
引用本文: 张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略：激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
shu
ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
Citation: ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
shu

    全文HTML

参考文献 (34)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计